KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors
01 May, 2021
– ReAlta Life Sciences, Inc. from Norfolk, Virginia closed a $20m Series A3 financing.
– The round was led by Marathon Pharma with participation from existing investors and new, undisclosed investors.
– The company intends to use the funds to advance multiple programs addressing ALI and HIE, including lead candidate RLS-0071, into Phase 2 clinical trials.